NCT03348618View on ClinicalTrials.gov

A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

PHASE4UnknownINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 24, 2017

Primary Completion Date

November 30, 2019

Study Completion Date

March 31, 2020

Conditions
Pediatric Acute-Onset Neuropsychiatric SyndromePediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Interventions
BIOLOGICAL

IVIG

Intravenous immunoglobulin

Trial Locations (3)

28204

Allergy, Asthma & Immunology Relief Research Institute, Charlotte

68046

Midwest Pediatrics, Papillion

80112

IMMUNOe Research Centers, Centennial

Sponsors

Collaborators (1)

Octapharma
All Listed Sponsors
collaborator

Octapharma

INDUSTRY

lead

IMMUNOe Research Centers

INDUSTRY

NCT03348618 - A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) | Biotech Hunter | Biotech Hunter